BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lazaar AL, Miller BE, Donald AC, Keeley T, Ambery C, Russell J, Watz H, Tal-Singer R; for 205724 Investigators. CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial. Respir Res 2020;21:149. [PMID: 32532258 DOI: 10.1186/s12931-020-01401-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Völs S, Kaisar-iluz N, Shaul ME, Ryvkin A, Ashkenazy H, Yehuda A, Atamneh R, Heinberg A, Ben-david-naim M, Nadav M, Hirsch S, Mitesser V, Salpeter SJ, Dzikowski R, Hayouka Z, Gershoni JM, Fridlender ZG, Granot Z. Targeted nanoparticles modify neutrophil function in vivo. Front Immunol 2022;13:1003871. [DOI: 10.3389/fimmu.2022.1003871] [Reference Citation Analysis]
2 Ngo ATP, Gollomp K. Building a better NET : Neutrophil extracellular trap targeted therapeutics in the treatment of infectious and inflammatory disorders. Res Pract Thromb Haemost 2022;6. [DOI: 10.1002/rth2.12808] [Reference Citation Analysis]
3 Milad N, Pineault M, Tremblay F, Routhier J, Lechasseur A, Beaulieu M, Aubin S, Morissette MC. Smoking status impacts treatment efficacy in smoke-induced lung inflammation: A pre-clinical study. Front Pharmacol 2022;13:971238. [DOI: 10.3389/fphar.2022.971238] [Reference Citation Analysis]
4 Su PP, Zhang L, He L, Zhao N, Guan Z. The Role of Neuro-Immune Interactions in Chronic Pain: Implications for Clinical Practice. JPR 2022;Volume 15:2223-48. [DOI: 10.2147/jpr.s246883] [Reference Citation Analysis]
5 Boff D, Russo RC, Crijns H, de Oliveira VLS, Mattos MS, Marques PE, Menezes GB, Vieira AT, Teixeira MM, Proost P, Amaral FA. The Therapeutic Treatment with the GAG-Binding Chemokine Fragment CXCL9(74-103) Attenuates Neutrophilic Inflammation and Lung Dysfunction during Klebsiella pneumoniae Infection in Mice. Int J Mol Sci 2022;23:6246. [PMID: 35682923 DOI: 10.3390/ijms23116246] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Keir HR, Chalmers JD. Neutrophil extracellular traps in chronic lung disease: implications for pathogenesis and therapy. Eur Respir Rev 2022;31:210241. [PMID: 35197267 DOI: 10.1183/16000617.0241-2021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
7 Billen M, Schols D, Verwilst P. Targeting chemokine receptors from the inside-out: discovery and development of small-molecule intracellular antagonists. Chem Commun (Camb) 2022;58:4132-48. [PMID: 35274633 DOI: 10.1039/d1cc07080k] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Van Hoof M, Boon K, Van Loy T, Schols D, Dehaen W, De Jonghe S. Identification of novel chemotypes as CXCR2 antagonists via a scaffold hopping approach from a thiazolo[5,4-d]pyrimidine. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114268] [Reference Citation Analysis]
9 Southworth T, Jevnikar Z, McCrae C, Singh D. A sputum 6-gene signature predicts airway inflammation endotypes and exacerbation frequency in chronic obstructive pulmonary disease. Biomark Med 2022. [PMID: 35176870 DOI: 10.2217/bmm-2021-0653] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Herrero-Cervera A, Soehnlein O, Kenne E. Neutrophils in chronic inflammatory diseases. Cell Mol Immunol 2022;19:177-91. [PMID: 35039631 DOI: 10.1038/s41423-021-00832-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 28] [Article Influence: 21.0] [Reference Citation Analysis]
11 Singh D. New Drugs for Airway Diseases. Encyclopedia of Respiratory Medicine 2022. [DOI: 10.1016/b978-0-08-102723-3.00170-0] [Reference Citation Analysis]
12 Tavares LP, Galvão I, Ferrero MR. Novel Immunomodulatory Therapies for Respiratory Pathologies. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00073-6] [Reference Citation Analysis]
13 Shen M, Du Y, Ye Y. Tumor-associated macrophages, dendritic cells, and neutrophils: biological roles, crosstalk, and therapeutic relevance. Medical Review 2021;1:222-43. [DOI: 10.1515/mr-2021-0014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Long MB, Chalmers JD. Treating Neutrophilic Inflammation in Airways Diseases. Arch Bronconeumol 2021. [PMID: 34866748 DOI: 10.1016/j.arbres.2021.11.003] [Reference Citation Analysis]
15 Wang HH, Cheng SL. From Biomarkers to Novel Therapeutic Approaches in Chronic Obstructive Pulmonary Disease. Biomedicines 2021;9:1638. [PMID: 34829866 DOI: 10.3390/biomedicines9111638] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
16 Keir HR, Chalmers JD. IL-6 trans-signalling: how Haemophilus surfs the NET to amplify inflammation in COPD. Eur Respir J 2021;58:2102143. [PMID: 34649972 DOI: 10.1183/13993003.02143-2021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Mincham KT, Bruno N, Singanayagam A, Snelgrove RJ. Our evolving view of neutrophils in defining the pathology of chronic lung disease. Immunology 2021;164:701-21. [PMID: 34547115 DOI: 10.1111/imm.13419] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
18 Baker JR, Donnelly LE. Leukocyte Function in COPD: Clinical Relevance and Potential for Drug Therapy. Int J Chron Obstruct Pulmon Dis 2021;16:2227-42. [PMID: 34354348 DOI: 10.2147/COPD.S266394] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
19 Belchamber KBR, Hughes MJ, Spittle DA, Walker EM, Sapey E. New Pharmacological Tools to Target Leukocyte Trafficking in Lung Disease. Front Immunol 2021;12:704173. [PMID: 34367163 DOI: 10.3389/fimmu.2021.704173] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
20 Keir HR, Chalmers JD. Pathophysiology of Bronchiectasis. Semin Respir Crit Care Med 2021;42:499-512. [PMID: 34261175 DOI: 10.1055/s-0041-1730891] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
21 Nakabo S, Romo-Tena J, Kaplan MJ. Neutrophils as Drivers of Immune Dysregulation in Autoimmune Diseases with Skin Manifestations. J Invest Dermatol 2021:S0022-202X(21)01225-2. [PMID: 34253374 DOI: 10.1016/j.jid.2021.04.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
22 Llanos-Paez C, Ambery C, Yang S, Tabberer M, Beerahee M, Plan EL, Karlsson MO. Improved Decision-Making Confidence Using Item-Based Pharmacometric Model: Illustration with a Phase II Placebo-Controlled Trial. AAPS J 2021;23:79. [PMID: 34080077 DOI: 10.1208/s12248-021-00600-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Matera MG, Calzetta L, Annibale R, Russo F, Cazzola M. Classes of drugs that target the cellular components of inflammation under clinical development for COPD. Expert Rev Clin Pharmacol 2021;14:1015-27. [PMID: 33957839 DOI: 10.1080/17512433.2021.1925537] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
24 Lin WC, Fessler MB. Regulatory mechanisms of neutrophil migration from the circulation to the airspace. Cell Mol Life Sci 2021;78:4095-124. [PMID: 33544156 DOI: 10.1007/s00018-021-03768-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
25 Trivedi A, Khan MA, Bade G, Talwar A. Orchestration of Neutrophil Extracellular Traps (Nets), a Unique Innate Immune Function during Chronic Obstructive Pulmonary Disease (COPD) Development. Biomedicines 2021;9:53. [PMID: 33435568 DOI: 10.3390/biomedicines9010053] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
26 Matera MG, Cazzola M, Page C. Prospects for COPD treatment. Curr Opin Pharmacol. 2020;56:74-84. [PMID: 33333428 DOI: 10.1016/j.coph.2020.11.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
27 Chiang CC, Korinek M, Cheng WJ, Hwang TL. Targeting Neutrophils to Treat Acute Respiratory Distress Syndrome in Coronavirus Disease. Front Pharmacol 2020;11:572009. [PMID: 33162887 DOI: 10.3389/fphar.2020.572009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 22.5] [Reference Citation Analysis]
28 Lo Bello F, Hansbro PM, Donovan C, Coppolino I, Mumby S, Adcock IM, Caramori G. New drugs under development for COPD. Expert Opinion on Emerging Drugs 2020;25:419-31. [DOI: 10.1080/14728214.2020.1819982] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]